Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Sofia A. Pereira; Umbelina Caixas; Teresa Branco; Isabel Germano; Fátima Lampreia; Ana L. Papoila; Emília C. Monteiro

doi:10.1111/j.1365-2125.2008.03238.x

Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Sofia A. Pereira, Umbelina Caixas, Teresa Branco, Isabel Germano, Fátima Lampreia, Ana L. Papoila, Emília C. Monteiro

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 ± 1.91 mg l ^-1) vs. co-infected individuals (2.37 ± 0.37 mg l ^-1). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.

Original language	English
Pages (from-to)	551-555
Number of pages	5
Journal	British Journal of Clinical Pharmacology
Volume	66
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2125.2008.03238.x
State	Published - Oct 2008
Externally published	Yes

Keywords

Efavirenz concentrations
Liver function
Viral hepatitis co-infection

Access to Document

10.1111/j.1365-2125.2008.03238.x

Cite this

@article{6f6c8e336002454a9d295bb661be2ccd,

title = "Efavirenz concentrations in HIV-infected patients with and without viral hepatitis",

abstract = "AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 ± 1.91 mg l -1) vs. co-infected individuals (2.37 ± 0.37 mg l -1). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.",

keywords = "Efavirenz concentrations, Liver function, Viral hepatitis co-infection",

author = "Pereira, {Sofia A.} and Umbelina Caixas and Teresa Branco and Isabel Germano and F{\'a}tima Lampreia and Papoila, {Ana L.} and Monteiro, {Em{\'i}lia C.}",

year = "2008",

month = oct,

doi = "10.1111/j.1365-2125.2008.03238.x",

language = "English",

volume = "66",

pages = "551--555",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

AU - Pereira, Sofia A.

AU - Caixas, Umbelina

AU - Branco, Teresa

AU - Germano, Isabel

AU - Lampreia, Fátima

AU - Papoila, Ana L.

AU - Monteiro, Emília C.

PY - 2008/10

Y1 - 2008/10

N2 - AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 ± 1.91 mg l -1) vs. co-infected individuals (2.37 ± 0.37 mg l -1). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.

AB - AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 ± 1.91 mg l -1) vs. co-infected individuals (2.37 ± 0.37 mg l -1). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.

KW - Efavirenz concentrations

KW - Liver function

KW - Viral hepatitis co-infection

UR - http://www.scopus.com/inward/record.url?scp=51649096977&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2008.03238.x

DO - 10.1111/j.1365-2125.2008.03238.x

M3 - Article

C2 - 18662298

AN - SCOPUS:51649096977

SN - 0306-5251

VL - 66

SP - 551

EP - 555

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 4

ER -

Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Abstract

Keywords

Access to Document

Fingerprint

Cite this